Can I read Radium-223 in Metastatic Castration Resistant Prostate Cancer on EtoBox?

Radium-223 in Metastatic Castration Resistant Prostate Cancer by Pal, SumantaK; Vuong, Winston; Sartor, Oliver is a Medicine article available to read on EtoBox.

What is Radium-223 in Metastatic Castration Resistant Prostate Cancer about?

In 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). For the next several years, there was a lull in drug approvals. However, from 2010 onwards, 5 additional therapies have been approved on the basis of showing a survival benefit in phase III studies. These agents include sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and (most recently) radium-223. Amongst radiopharmaceuticals currently used for advanced prostate cancer (e.g. samarium-153 and strontium-89), radium-223 possesses several unique properties. As an alpha-emitting compound, the agent produces a high-energy output over a short range, facilitating selective destruction of tissue within the bone in the region of osteoblastic lesions while sparing surrounding normal tissue. The current review will outline biological rationale for radium-223 and also provide an overview of preclinical and clinical development of the agent. Rational sequencing of radium-223 and combinations, in the increasingly complex landscape of mCRPC will be discussed, along with factors influencing clinical implementation.

Who reads Radium-223 in Metastatic Castration Resistant Prostate Cancer?

Author

Pal, SumantaK; Vuong, Winston; Sartor, Oliver

Publisher

Nature Publishing Group; Medknow Publications; Medknow (ISSN 1008-682X)

Published

2014

Language

EN

Field

Medicine (Health Sciences)